Clinicopathological Significance of DLC-1 Expression in Cancer: a Meta-Analysis

  • Jiang, Yan (Department of Basic Medical Science, Department of Human Anatomy, Histology and Embryology, Institute of Neuroscience, Changsha Medical University) ;
  • Li, Jian-Ming (Department of Basic Medical Science, Department of Human Anatomy, Histology and Embryology, Institute of Neuroscience, Changsha Medical University) ;
  • Luo, Huai-Qing (Department of Basic Medical Science, Department of Human Anatomy, Histology and Embryology, Institute of Neuroscience, Changsha Medical University)
  • Published : 2015.11.04


Background: Recent reports have shown that DLC-1 is widely expressed in normal tissues and is down-regulated in a wide range of human tumors, suggesting it may act as a tumor suppressor gene. We conducted a meta-analysis to determine the correlation between DLC-1 expression and clinicopathological characteristics in cancers. Materials and Methods: A detailed literature search was made for relevant publications from PubMed, EMBASE, Cochrane library databases, Web of Science, CNKI. The methodological quality of the studies was also evaluated. Analyses of pooled data were performed and odds ratios (ORs) were calculated and summarized. Results: Final analysis was performed of 1,815 cancer patients from 19 eligible studies. We observed that DLC- 1 expression was significantly lower in cancers than in normal tissues. DLC-1 expression was not found to be associated with tumor differentiation status. However, DLC-1 expression was obviously lower in advance stage than in early-stage cancers and was more down-regulated in metastatic than non-metastatic cancers. Conclusions: The results of our meta-analysis suggested that DLC-1 expression is significantly lower in cancers than in normal tissues. Aberrant DLC-1 expression may play an important role in cancer genesis and metastasis.


DLC-1 expression;metastasis;meta-analysis;cancer


  1. Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-101.
  2. Duval S,Tweedie R (2000). Trim and fill: A simple funnel-plotbased method of testing and adjusting for publication bias in meta-analysis. Biometrics, 56, 455-63.
  3. Egger M, Davey Smith G, Schneider M, et al (1997). Bias in metaanalysis detected by a simple, graphical test. BMJ, 315, 629-34.
  4. Etienne-Manneville S, Hall A (2002). Rho GTPases in cell biology. Nature, 420, 629-35.
  5. Fan DM, Shi HR (2011). Pilot study: alteration of deleted in liver cancer1 and phosphorylated focal adhesion kinase Y397 cytoplasmic expression and the prognostic value in advanced epithelial ovarian carcinoma. Int J Mol Sci, 12, 8489-501.
  6. Fang R, Huirong S, Zhimin C, et al (2012). Protein expression of DLC-1, FAK and Crk-associated 130 kDaP in epithelial ovarian cancer and their significance. Modern Oncol, 21, 152-5.
  7. Feng X, Ren C, Zhou W, et al (2014). Promoter hypermethylation along with LOH, but not mutation, contributes to inactivation of DLC-1 in nasopharyngeal carcinoma. Mol Carcinog, 53, 858-70.
  8. Guan M, Zhou X, Soulitzis N, et al (2006). Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications. Clin Cancer Res, 12, 1412-9.
  9. Heering J, Erlmann P, Olayioye MA (2009). Simultaneous loss of the DLC1 and PTEN tumor suppressors enhances breast cancer cell migration. Exp Cell Res, 315, 2505-14.
  10. Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58.
  11. Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60.
  12. Homma Y, Emori Y (1995). A dual functional signal mediator showing RhoGAP and phospholipase C-delta stimulating activities. EMBO J, 14, 286-91.
  13. Hua T, Xiaojun Y, Tie Z, et al (2010). The manifestation of DLC- 1 proteins in gastric carcinoma and its clinic-pathological significance. Anhui Med J, 31, 1328-31.
  14. Liu JB ZS, Shi MX, Shao BF, Zhang YX (2008). Relationship between methylation status of DLC-1 gene and metastasis of hepatocellular carcinoma. World Chinese J Digestol, 11, 1237-40.
  15. McShane LM, Altman DG, Sauerbrei W, et al (2005). Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst, 97, 1180-4.
  16. Mingrui S, Hui C, Xia-yun Z, et al (2014). Expression of DLC-1 and cycfin D1 and their clinical significance in cervical squamous cell carcinoma. Chinese J Diagnostic Pathol, 21, 633-6.
  17. Moon SY, Zheng Y (2003). Rho GTPase-activating proteins in cell regulation. Trends Cell Biol, 13, 13-22.
  18. Peng D, Ren CP, Yi HM, et al (2006). Genetic and epigenetic alterations of DLC-1, a candidate tumor suppressor gene, in nasopharyngeal carcinoma. Acta Biochim Biophys Sin (Shanghai), 38, 349-55.
  19. Peng H, Long F, Wu Z, et al (2013). Downregulation of DLC-1 gene by promoter methylation during primary colorectal cancer progression. Biomed Res Int, 2013, 181384.
  20. Qian X, Li G, Asmussen HK, et al (2007). Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities. Proc Natl Acad Sci U S A, 104, 9012-7.
  21. Qin Y, Chu B, Gong W, et al (2014). Inhibitory effects of deleted in liver cancer 1 gene on gallbladder cancer growth through induction of cell cycle arrest and apoptosis. J Gastroenterol Hepatol, 29, 964-72.
  22. Quanrui W, Zhimei C (2012). Expression and signiiieance of DLC- 1 protein in gallbladder carcinoma. J Hepatopancreatobiliarv Surg, 24, 214-6.
  23. Ren F, Shi H, Zhang G, et al (2013). Expression of deleted in liver cancer 1 and plasminogen activator inhibitor 1 protein in ovarian carcinoma and their clinical significance. J Exp Clin Cancer Res, 32, 60.
  24. Seng TJ, Low JS, Li H, et al (2007). The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation. Oncogene, 26, 934-44.
  25. Steels E, Paesmans M, Berghmans T, et al (2001). Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J, 18, 705-19.
  26. Tcherkezian J, Lamarche-Vane N (2007). Current knowledge of the large RhoGAP family of proteins. Biol Cell, 99, 67-86.
  27. Wang Y, Lei R, Zhuang X, et al (2014). DLC1-dependent parathyroid hormone-like hormone inhibition suppresses breast cancer bone metastasis. J Clin Invest, 124, 1646-59.
  28. Guan CN, Zhang PW, Lou HQ, et al (2012). DLC-1 expression levels in breast cancer assessed by qRT- PCR are negatively associated with malignancy. Asian Pac J Cancer Prev, 13, 1231-33.
  29. Xue YZ, Wu TL, Wu YM, et al (2013). DLC-1 is a candidate biomarker methylated and down-regulated in pancreatic ductal adenocarcinoma. Tumour Biol, 34, 2857-61.
  30. Yam JW, Ko FC, Chan CY, et al (2006). Interaction of deleted in liver cancer 1 with tensin2 in caveolae and implications in tumor suppression. Cancer Res, 66, 8367-72.
  31. Yang C, Tiankang G, Yuntao M, et al (2013a). Expression and clinical significance of DLC-1and MMP-9 in gastric carcinoma. J Ningxia Med University, 35, 872-6.
  32. Yang C, Wu D, Jia J, et al (2013b). DLC1 as a regulator of proliferation, invasion, cell cycle, and apoptosis in cutaneous squamous cell carcinoma. Tumour Biol, 34, 2633-43.
  33. Yang X, Popescu NC, Zimonjic DB (2011). DLC1 interaction with S100A10 mediates inhibition of in vitro cell invasion and tumorigenicity of lung cancer cells through a RhoGAPindependent mechanism. Cancer Res, 71, 2916-25.
  34. Yang XY, Guan M, Vigil D, et al (2009). p120Ras-GAP binds the DLC1 Rho-GAP tumor suppressor protein and inhibits its RhoA GTPase and growth-suppressing activities. Oncogene, 28, 1401-9.
  35. Yuan BZ, Durkin ME, Popescu NC (2003). Promoter hypermethylation of DLC-1, a candidate tumor suppressor gene, in several common human cancers. Cancer Genet Cytogenet, 140, 113-7.
  36. Yuan BZ, Miller MJ, Keck CL, et al (1998). Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res, 58, 2196-9.
  37. Yufei L, Shengrong S, Chuan C, et al (2014). Protein expression and promoter methylation of deleted in liver cancer-1 gene in papilarry thyroid carcinoma. Chin J Exp Surg, 31, 152-5.
  38. Yufei L, Zhaoxiang Z, Lin H, et al (2010). Expression of DLC1 protein and DLC1-mRNA in breast carcinoma and their clinical significance. Chinese J Clin Oncol, 37, 866-9.
  39. Yujie Z, Qingshuai F, Fangling N, et al (2014). Expressions and clinical significance of DLC1 and ROCK1 in non small cell lung cancer. J Int Oncol, 41, 688-91.
  40. Yun F, Huixing Z, Junhong L, et al (2011). Expression of deleted in liver cancer 1 and phosphorelated focal adhesion kinase in breast cancer. J South Med Univ, 31, 1448-551.
  41. Zhang T, Zheng J, Liu C, et al (2009). Expression of DLC-1 in clear cell renal cell carcinoma: prognostic significance for progression and metastasis. Urol Int, 82, 380-7.
  42. Zhefeng Y, Xisheng Y, Bin D, et al (2015). Clinical significance of DLC-1 expression in hepatic cancer. Modern Oncol, 23, 644-6.1